Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved Ranitidine hydrochlorideis a histamine H2-receptor antagonist that inhibits stomach acid production.
      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Active Pharmaceutical Ingredients  TAJ PHARMACEUTICALS LIMITED

Ranitidine Hydrochloride Manufacturers in India Suppliers Ranitidine Hydrochloride Exporters Distributors Ranitidine Hydrochloride api active pharmaceuticals ingredients Ranitidine Hydrochloride manufacturers Side Effects bulk drugs raw material Ranitidine Hydrochloride companies Side Effects Importers Ranitidine Hydrochloride Ranitidine Hydrochloride Exporters Ranitidine Hydrochloride exporters FDA Ranitidine Hydrochloride DMF Symptoms Generic Taj Pharmaceuticals Ltd.

Pharmaceuticals API Manufacturer Ranitidine Hydrochloride, Ranitidine Hydrochloride manufacturer India, Ranitidine Hydrochloride product, Ranitidine Hydrochloride products, Api preparation, Certificate of Analysis API manufacturer product, Ranitidine Hydrochloride anti ulcer product, Certificate of Origin COA Ranitidine Hydrochloride COS Ranitidine Hydrochloride, pharmaceutical generic, pharmaceutical drug, medical, Ranitidine Hydrochloride pharma healthcare, pharma patents, contract MSDS manufacturing Trader Ranitidine Hydrochloride pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Ranitidine Hydrochloride expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Ranitidine Hydrochloride DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Ranitidine Hydrochloride ingredients, api, HIV Ranitidine Hydrochloride, tablets, capsules, syrup & protein Ranitidine Hydrochloride powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Ranitidine Hydrochloride gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Ranitidine Hydrochloride WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API
   Pharmaceuticals API List >>
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
Research for medication




























 


 

 
HOME >> API >> API List 3 >> Ranitidine Hydrochloride >> Precautions

Ranitidine Hydrochloride CAS number 66357-35-5

PRECAUTIONS
Ranitidine Hydrochloride CAS number 66357-35-5

Before administering ranitidine,

* tell your doctor and pharmacist if you are allergic to ranitidine or any other drugs.
* tell your doctor and pharmacist what prescription and nonprescription medications you are taking, especially acetaminophen  anticoagulants ('blood thinners') such as warfarin , propantheline, and vitamins.
* tell your doctor if you have or have ever had kidney or liver disease or acute porphyria.
* tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking ranitidine, call your doctor.

Central Nervous System: Rarely, malaise, dizziness, somnolence, insomnia, and vertigo. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.

Cardiovascular: As with other H2-blockers, rare reports of arrhythmias such as tachycardia, bradycardia, atrioventricular block, and premature ventricular beats.

Gastrointestinal: Constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, and rare reports of pancreatitis.

Hepatic: There have been occasional reports of hepatocellular, cholestatic, or mixed hepatitis, with or without jaundice. In such circumstances, ranitidine should be immediately discontinued. These events are usually reversible, but in rare circumstances death has occurred. Rare cases of hepatic failure have also been reported. In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg intravenously 4 times daily for 7 days, and in 4 of 24 subjects receiving 50 mg intravenously 4 times daily for 5 days.

Musculoskeletal: Rare reports of arthralgias and myalgias.

Other: Rare cases of hypersensitivity reactions (e.g., bronchospasm, fever, rash, eosinophilia), anaphylaxis, angioneurotic edema, acute interstitial nephritis, and small increases in serum creatinine.Pregnancy: Teratogenic Effects: Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 160 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Ranitidine HCl. There are, however, no adequate and well-controlled studies in pregnant women.

Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.Pediatric Use: The safety and effectiveness of Ranitidine HCl have been established in the age-group of 1 month to 16 years for the treatment of duodenal and gastric ulcers, gastroesophageal reflux disease and erosive esophagitis, and the maintenance of healed duodenal and gastric ulcer.

Use of Ranitidine HCl in this age-group is supported by adequate and well-controlled studies in adults, as well as additional pharmacokinetic data in pediatric patients and an analysis of the published literatureGeriatric Use: Of the total number of subjects enrolled in US and foreign controlled clinical trials of oral formulations of Ranitidine HCl, for which there were subgroup analyses, 4,197 were 65 and over, while 899 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE
SIDE EFFECTS
PRECAUTIONS >>
INTERACTION
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj pharmaceuticals API Logo

Ranitidine Hydrochloride

More Api at Taj Pharmaceuticals Ltd.

Quetiapine Fumarate

Quinine Sulfate

Rabeprazole Sodium

Ramipril

Ranitidine Hydrochloride

Risperidone

Rivastigmine Tartrate

Rizatriptan

Rosiglitazone Maleate

Telmisartan

Tamsulosin HCl

Tegaserod Maleate

Terbinafine HCl

Tolterodine Tartrate

Trandolapril

Valdecoxib

Valsartan

Venlafaxine

Voriconazole

Zolmitriptan

Zonisamide

Primidone

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap
 

taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.